LadRx Corp (LADX)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Stephen Snowdy
Employees:
3
11726 SAN VICENTE BOULEVARD, SUITE 650, LOS ANGELES, CA, 90049
310-826-5648

CytRx Corporation focuses on oncology and rare diseases. It engages in the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies. The company's lead candidates include linker activated drug release (LADR) -7, LADR-8,. and Aldoxorubicin that binds to circulating albumin in the bloodstream and to concentrate the drug at the site of the tumor.

Data derived from most recent annual or quarterly report
Market Cap 21.34 Million Shares Outstanding38.8 Million Avg 30-day Volume 102.633 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.04
Price to Revenue0.0 Debt to Equity0.0805 EBITDA-11.678 Million
Price to Book Value0.0 Operating Margin0.0 Enterprise Value15.255 Million
Current Ratio1.366 EPS Growth0 Quick Ratio1.335
1 Yr BETA 0.5354 52-week High/Low / Profit Margin0.0
Operating Cash Flow Growth-136.5921 Altman Z-Score-208.9207 Free Cash Flow to Firm -8.773 Million
View SEC Filings from LADX instead.

View recent insider trading info

LadRx Corp YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding LADX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding LADX

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 3: filed on 2022-07-28 by CLAIBORNE CARY J
  • 4: filed on 2022-01-12 by SNOWDY STEPHEN
  • 3: filed on 2022-01-12 by SNOWDY STEPHEN
  • 4/A: filed on 2022-01-11 by SIMPSON JENNIFER K.
  • 4: filed on 2021-12-17 by SIMPSON JENNIFER K.
  • 3: filed on 2021-08-11 by SIMPSON JENNIFER K.
  • 4: filed on 2020-08-20 by BRIEN EARL W
  • 4: filed on 2020-08-13 by KRIEGSMAN STEVEN A
  • 4: filed on 2020-08-13 by IGNARRO LOUIS
  • 4: filed on 2020-08-13 by CALDWELL JOEL K

    • Events (8k)

  • 8-K: filed on 2022-12-30:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-09-23:
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-07-27:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-06-02:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-05-19:
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-21:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-16:
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-10:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-01-26:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-01-04:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    CLAIBORNE CARY J

    • Director
    		 0 2022-07-27 1

    SNOWDY STEPHEN CHIEF EXECUTIVE OFFICER

    • Officer
    		 0 2022-01-10 0

    SIMPSON JENNIFER K.

    • Director
    		 50,000 2021-12-15 0

    BRIEN EARL W

    • Director
    		 590,247 2020-08-14 0

    KRIEGSMAN STEVEN A CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 3,668,038 2020-08-07 0

    IGNARRO LOUIS

    • Director
    		 600,785 2020-08-07 0

    CALDWELL JOEL K

    • Director
    		 335,373 2020-08-07 0

    CALOZ JOHN Y CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2019-12-13 0

    CURTIS ERIC PRES., CHIEF OPERATING OFFICER

    • Officer
    		 0 2018-05-03 0

    KRATZ FELIX VICE PRESIDENT DRUG DISCOVERY

    • Officer
    		 0 2017-12-15 0

    CHAWLA SHANTA M.D. SENIOR VP-DRUG DEVELOPMENT

    • Officer
    		 2,100 2017-06-13 0

    RUBINFELD JOSEPH

    • Director
    		 0 2016-12-15 0

    LEVITT DANIEL J EVP AND CHIEF MEDICAL OFFICER

    • Officer
    		 0 2016-12-15 0

    WIELAND DOUGLAS SCOTT SR VP - DRUG DEVELOPMENT

    • Officer
    		 0 2016-12-15 0

    CHAWLA ANITA J

    • Director
    		 0 2016-12-15 0

    WARE OLIVIA C CHIEF COMMERCIAL OFFICER

    • Officer
    		 0 2016-01-11 0

    LEVIN BEN SVP-LEGAL AFFAIRS/GC/SECY

    • Officer
    		 0 2015-12-15 0

    COHEN CHERYL

    • Director
    		 0 2015-12-15 0

    SELTER ERIC JAY

    • Director
    		 0 2015-12-15 0

    WENNEKAMP RICHARD L.

    • Director
    		 0 2014-12-15 0

    LINK MAX

    • Director
    		 0 2013-12-10 0

    SELTER MARVIN R

    • Director
    		 0 2013-12-10 0

    PATTERSON SCOTT BRADFORD

    • 10% Owner
    		 4,577,605 2013-12-10 0

    GEYER DAVID SCOTT SR. V.P. OF MANUFACTURING

    • Officer
    		 0 2011-12-12 0

    BARBER JACK R CHIEF SCIENTIFIC OFFICER

    • Officer
    		 0 2009-07-01 0

    SHAH JAISIM SR. VP - BUSINESS DEVELOPMENT

    • Officer
    		 0 2009-05-04 0

    FOGELMAN MITCHELL K CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2008-11-21 0

    NG SHI CHUNG SR VP RESEARCH & DEVELOPMENT

    • Officer
    		 0 2008-11-21 0

    TEPPER MARK VICE PRESIDENT

    • Officer
    		 250,000 2007-05-02 0

    NATALIZIO MATT CHIEF FINANCIAL OFFICER

    • Officer
    		 50,000 2006-06-16 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    LADRX CORP LADX 2023-01-26 22:15:03 UTC -3.8925 8.2125 700000
    LADRX CORP LADX 2023-01-26 21:45:03 UTC -3.8925 8.2125 700000
    LADRX CORP LADX 2023-01-26 21:15:04 UTC -3.8925 8.2125 700000
    LADRX CORP LADX 2023-01-26 20:45:03 UTC -3.8925 8.2125 700000
    LADRX CORP LADX 2023-01-26 20:15:04 UTC -3.8925 8.2125 700000
    LADRX CORP LADX 2023-01-26 19:45:03 UTC -3.8925 8.2125 700000
    LADRX CORP LADX 2023-01-26 19:15:04 UTC -3.8925 8.2125 700000
    LADRX CORP LADX 2023-01-26 18:45:03 UTC -3.8925 8.2125 700000
    LADRX CORP LADX 2023-01-26 18:15:04 UTC -3.8925 8.2125 700000
    LADRX CORP LADX 2023-01-26 17:45:04 UTC -3.8925 8.2125 700000
    LADRX CORP LADX 2023-01-26 17:15:04 UTC -3.8925 8.2125 700000
    LADRX CORP LADX 2023-01-26 16:45:03 UTC -3.8925 8.2125 700000
    LADRX CORP LADX 2023-01-26 16:15:04 UTC -3.8925 8.2125 700000
    LADRX CORP LADX 2023-01-26 15:45:03 UTC -3.8925 8.2125 700000
    LADRX CORP LADX 2023-01-26 15:15:04 UTC -3.8925 8.2125 700000
    LADRX CORP LADX 2023-01-26 14:45:04 UTC -3.8925 8.2125 700000
    LADRX CORP LADX 2023-01-26 14:15:03 UTC -3.8925 8.2125 700000
    LADRX CORP LADX 2023-01-26 13:45:03 UTC -3.8925 8.2125 700000
    LADRX CORP LADX 2023-01-26 13:15:04 UTC -3.8925 8.2125 700000
    LADRX CORP LADX 2023-01-26 12:45:04 UTC -3.8925 8.2125 700000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments